|
|
|
Chenomx offers software and services for generating, classifying, and interpreting metabolic profiles obtained from biological fluids using magnetic resonance spectroscopy.
|
|
QOM "No amount of experimentation can ever prove me right; a single experiment can prove me wrong.'"
Albert Einstein
|
|
|
Greetings!
Welcome to the December edition of our Discover More
newsletter.
|
 |
Happy Holidays
|

As we head into the final days of 2009, we all
are kept busy with holiday errands, social gatherings, and tying up loose ends
before we take some time to relax. So, at this time, all of us at Chenomx would
like to take this opportunity to extend our best wishes for a happy and safe
holiday season and a prosperous 2010 to all of you. We thank you for
your continued support and interest in our metabolic profiling software and services. If any of you still have some money
remaining in your 2009 budgets and are interested in purchasing a license of
Chenomx NMR Suite before December 31, 2009, then you will be pleased to know we
are still offering our seat sale special. Please contact us or see the box at the bottom of this
page for details. Hurry though, 2009 is almost over! Once
again, happy holidays to everyone! |
 |
Publications Using Chenomx NMR Suite |
 In the November 2009 issue of the Journal of Proteome Research, there was a study published by Joyner et al. entitled Probing the Metabolic Aberrations Underlying
Mutant Huntingtin Toxicity in Yeast and Assessing Their Degree of
Preservation in Humans and Mice. This paper used the patented " Targeted Profiling" technology of Chenomx NMR Suite to help find conserved metabolic biomarkers that are associated with mutant
huntingtin gene expression. The mutant huntingtin protein is responsible
for causing Huntington's disease; however, its mode of action is unknown. Moreover, the problem is further complicated due to a combination of
loss-of-function effects (due to the gene's mutation) and
gain-of-toxic-function properties attributable to the protein. In this comparative study, the researchers looked at data from yeast, mice, and humans in order to gain
insight as to which metabolic disruptions arise from these two phenomena.
This allowed them to use that information in a follow-up metabolomics study that has just been completed to design new drugs to combat mutant huntingtin toxicity.
Here is what Dr. Robert Cichewicz (one of the authors of the above study) from the University of Oklahoma had to say about his experience with Chenomx NMR Suite: "The Chenomx
software was instrumental to the success of the project and we were very happy
with its performance. I now am putting a new student to work using the
metabolomics software to address other biochemical questions."
To see the abstract and sign-in to read this paper click here. If you have published any material using Chenomx NMR Suite, please do not hesitate to let us know so that we can mention it in this newsletter. We would love to see it!
For other publications, case studies, news, and application notes using Chenomx NMR Suite click here.
|
 |
Upcoming Metabolomics Conference
|
Chenomx is proud to be a silver sponsor at the first International Metabolomics Symposium taking place March 10-12, 2010, in Freising-Weihenstephanin, Germany. This informative conference will focus on new analytic methods,
late-breaking discoveries, as well as challenges and pitfalls in metabolomics
studies. Leading scientists will discuss the value of Metabolomics in basic
science applications, in diagnostics and in nutrition and food research.
You can register for this 2-1/2 day conference and get more information by clicking here.
|
 |
Chenomx NMR Suite 6.0 Tips
|

When using the Library Manager module in
Chenomx NMR Suite 6.0, you can edit a compound in the Compound Table by right-clicking on its entry and selecting Send to Compound Builder. As soon as you save your changes in Compound Builder, they are available in all Compound Sets containing the compound. |
 |
Did You Know?
|
In 10 minutes, a hurricane releases more energy than all of the world's nuclear weapons combined.
|
|
|
Please direct any comments or questions to:
Alex Cherniavsky
|
|
|